Dose 2 gevokizumab
Phase 3Terminated 0 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Uveitis
Conditions
Uveitis
Trial Timeline
Mar 1, 2014 → Dec 1, 2017
NCT ID
NCT02258854About Dose 2 gevokizumab
Dose 2 gevokizumab is a phase 3 stage product being developed by XOMA for Uveitis. The current trial status is terminated. This product is registered under clinical trial identifier NCT02258854. Target conditions include Uveitis.
What happened to similar drugs?
3 of 20 similar drugs in Uveitis were approved
Approved (3) Terminated (8) Active (9)
Hype Score Breakdown
Clinical
17
Activity
0
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02258854 | Phase 3 | Terminated |
Competing Products
20 competing products in Uveitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| triamcinolone acetonide (Triesence®) | Clearside Biomedical | Phase 1/2 | 22 |
| 4 mg CLS-TA Suprachoriodal Injection | Clearside Biomedical | Phase 3 | 30 |
| Baricitinib + Adalimumab | Eli Lilly | Phase 3 | 44 |
| Ixekizumab Prefilled Syringe | Eli Lilly | Approved | 39 |
| adalimumab | AbbVie | Phase 3 | 40 |
| Adalimumab + Prednisone + Placebo | AbbVie | Phase 3 | 40 |
| Adalimumab + Prednisone + Placebo | AbbVie | Phase 3 | 40 |
| Adalimumab | AbbVie | Approved | 43 |
| FTY720 + Oral Corticosteroid | Novartis | Phase 2 | 27 |
| AIN457 | Novartis | Phase 3 | 32 |
| Myfortic | Novartis | Pre-clinical | 22 |
| AIN457 + AIN457 + Placebo AIN457 | Novartis | Phase 3 | 32 |
| LFG316 + Conventional Therapy | Novartis | Phase 2 | 35 |
| Ranibizumab | Novartis | Phase 2 | 35 |
| AIN457 + Placebo | Novartis | Phase 3 | 32 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 32 |
| AEB071 | Novartis | Phase 2 | 35 |
| AIN457 + AIN457 + AIN457 + Placebo | Novartis | Phase 3 | 32 |
| Myfortic + Decortin | Novartis | Phase 3 | 40 |
| AIN457 + AIN 457 + AIN457 | Novartis | Phase 2 | 35 |